/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

J

Juan‐Manuel Sancho

Universitat Autònoma de Barcelona(ES)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

404

Papers

5.4K

Citations

36

h-index

101

i10-index

Juan‐Manuel Sancho is an academic researcher from Universitat Autònoma de Barcelona. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research & Viral-associated cancers and disorders. The author has an h-index of 36, co-authored 344 publications.

ORCID: 0000-0001-7168-6538

Research Topics

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Viral-associated cancers and disorders CNS Lymphoma Diagnosis and Treatment CAR-T cell therapy research

Papers by this author

works

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

2018 · The Lancet Haematology · 63 citations

https://doi.org/10.1016/s2352-3026(18)30157-1

Michinori Ogura Juan‐Manuel Sancho Seok‐Goo Cho Hideyuki Nakazawa

Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020

2022 · British Journal of Haematology · 20 citations

https://doi.org/10.1111/bjh.18597

Minna Harmanen Mika Hujo Reijo Sund Marc Sorigué

Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study

2021 · Clinical Lymphoma Myeloma & Leukemia · 13 citations

https://doi.org/10.1016/j.clml.2021.08.005

Larry W. Kwak Juan‐Manuel Sancho Seok‐Goo Cho Hideyuki Nakazawa

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

2021 · Investigational New Drugs · 7 citations

https://doi.org/10.1007/s10637-020-01054-6

Monica Balzarotti Massimo Magagnoli Miguel Canales Paolo Corradini

Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study

2023 · Transplantation and Cellular Therapy · 5 citations

https://doi.org/10.1016/j.jtct.2023.08.026

Mariana Bastos‐Oreiro Antonio Gutiérrez Gloria Iacoboni Lucía López‐Corral

Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain

2022 · Leukemia & lymphoma/Leukemia and lymphoma · 4 citations

https://doi.org/10.1080/10428194.2022.2053531

Josep‐María Ribera Josep‐María Ribera Olga García Buenaventura Buendía-Ureña

Research topics

topics

Lymphoma Diagnosis and Treatment

Chronic Lymphocytic Leukemia Research

Viral-associated cancers and disorders

CNS Lymphoma Diagnosis and Treatment

CAR-T cell therapy research

Chat about Author

Papers

Chat

Click to start Chat